|
Selected Non-Hodgkin's Lymphoma abstracts from the
American Society of Hematology (ASH) 2009 convention in New Orleans http://ash.confex.com/ash/2009/webprogram/start.html List compiled by Greg Dafoe |
Non-Hodgkin's Lymphoma Cyberfamily Home
Table of contents
-
Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster I
-
Clinical Results - Allogeneic Matched Related Donor Transplantation Poster I
-
Clinical Results - Alternative Donor Transplantation Poster I
-
Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster I
-
Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster I
-
Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster I
-
Clinical Results - Allogeneic Matched Related Donor Transplantation: Lymphoid Malignancies/Myeloma
-
Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster II
-
Clinical Results - Allogeneic Matched Related Donor Transplantation Poster II
-
Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster II
-
Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster II
-
Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster II
-
Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster II
-
Lymphoma: Chemotherapy, excluding Pre-Clinical Models - Non-Hodgkin Lymphoma: Therapy
-
Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Genetic Factors in Lymphoma
-
Clinical Care, Recurrence, Secondary Neoplasia and Late Complications After Transplantation II
-
Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Indolent Non-Hodgkin's Lymphoma: Biology
-
Clinical Results - Allogeneic Matched Related Donor Transplantation Poster III
-
Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster III
-
Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster III
-
Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster III
-
Clinical Results - Autologous Transplantation: Lymphoma and CLL
-
Lymphoma: Chemotherapy, excluding Pre-Clinical Models - New Treatments
-
Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Non-Hodgkin's Lymphoma: Biology
1133 Late-Onset Hemorrhagic Cystitis in Children After Hematopoietic Stem Cell Transplantation (HSCT) for Thalassemia and Sickle Cell Anemia: A Prospective Evaluation of Polyoma (BK) Virus Infection and Treatment with Cidofovir (CDV)
1134 Response of 864 Patients to Steroids as Primary Therapy for Acute Gvhd at a Single Institution: Day 28 Response Is the Best Endpoint to Predict Transplant-Related Mortality
1135 Elevated Serum Ferritin Predicts the Delay of Engraftment and High Incidence of Blood Stream Infection within 100 Days After Allogeneic Hematopoietic Stem Cell Transplantation
1136 High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation
1137 Immunogenicity of the Live Attenuated Varicella Vaccine Following Allogeneneic HCT
1138 MICA-129 Genotype, Soluble MICA and Anti-MICA Antibodies as Biomarkers of Chronic Graft Versus Host Disease
1139 Evaluation of NIH Consensus Criteria for Classification of Late Acute and Chronic Gvhd in Reduce Intensity Conditioning (RIC) Stem Cell Transplantation (SCT)
1140 High Dose Valacyclovir Is Highly Effective to Prevent Cytomegalovirus and Other Herpes Viruses Viremia After Allogeneic Stem Cell Transplantation
1141 Long-Term Follow-up of HCV Infected Stem Cell Transplant Patients and Effects of Antiviral Therapy
1142 Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies
1143 The Optimal Initiation Timing for Cyclosporine in Allogeneic Transplantation, Earlier Is Better with the Price of Higher Rate of Chronic Gvhd
1144 Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies – A Curative Approach When Performed as a Primary Therapeutic Modality: A Single Center Experience
1145 Correlations Between Host Cellular Immune Responses and Adenovirus (AdV) Associated Complications in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation
1146 Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
1147 Fludarabine, Cytarabine, Busulphan, and Cyclophosphamide (FABC) as Conditioning Regimen in Hematopoietic Stem Cell Transplantation for Treatment of 92 Patients with Hematologic Malignancies
1148 A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation
1149 Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age
1150 Early Detection of Isohemagglutinin From Donor Lymphocytes Has Impact On Acute Graft-Versus-Host Disease After Minor ABO-Incompatible Hematopoietic Stem Cell Transplantation
1151 Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study
1152 Effect of KGF (Palifermin) On Immune Reconstitution After Autologous Transplantation for Multiple Myeloma
1153 Oral Beclomethasone Dipropionate Monotherapy as An Initial Treatment for Stage 1-2 Gastrointestinal Tract Acute Graft-Versus-Host Disease Following Unrelated Cord Blood Transplantation
1154 Influence of Genetic Variability of GSTM1 and GSTT1 Null Alleles Between Donor and Recipient in the Development of Acute Graft Versus Host Disease
1155 "ATG16 L1 a Additional Risk Factor for TRM After allogeneic Stem Cell Transplantation "
1156 Collagen and Elastin Degradation Products as Potential Biomarkers for Chronic Graft-Versus-Host Disease (cGVHD)
1157 Immunotherapy with Anti-CD3 x Anti-CMV Bispecific Antibody (CMVBi) Armed Donor Derived Activated T Cells (ATC) – A Novel Strategy against Cytomegalovirus (CMV) Post Allogeneic Stem Cell Transplantation (SCT)
1158 Association Between TNF and TNF Receptor II Gene Polymorphisms and Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Haematopoietic Stem Cell Transplantation within Chinese Population
1159 Donor Inflammatory Gene Polymorphisms Are Associated with Early Bacterial Infection After Unrelated Allogeneic Haematopoietic Stem Cell Transplantation
1160 Proportion of IL-17A Producing CD4+ Cells Increases in Response to Alloreactivity as Part of a Network Involving Memory and Regulatory Cells Post HSCT
1161 Clinical Significance of EBV-Associated LPD After Cord Blood Transplantation
1162 Clinical Characteristics and GVL Effect of Chronic Graft-Versus-Host disease Following Reduced-Intensity Umbilical Cord Blood Transplantation (RICBT)
1163 Successful High-Dose Ribavirin Treatment of Respiratory Syncytial Virus-Induced Tracheobronchitis and Pneumonia Occuring Pre-Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients
1164 Proteomic Screening Applied to the Diagnosis of Chronic Graft-Versus-Host-Disease
1165 Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients
1166 Prognostic Significance of Complement System Activation After Allogeneic Hematopoietic Stem Cell Transplantation
1167 Factor VIII Is a Potential Autosomal B Cell Minor Histocompatibility Antigen in Chronic Gvhd
1168 Prospective Study of Oral Valganciclovir for Pre-Emptive Therapy of Cytomegalovirus After Allogeneic Stem Cell Transplantation
1169 Influenza A H1N1 Virus Infection in Two Hematopoietic Stem Cell Transplant Recipients
1170 Identification of Low Frequency Multiple Novel Aspergillus Fumigatus Specific MHC Class II Epitopes and Rapid Generation of An Aspergillus-Specific T-Cell Product Based On Activation Dependent Expression of CD154
1171 Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies
1172 Tacrolimus, Mini-Methotrexate and Mycophenolate Mofetil Is Safe and Effective as Acute Gvhd Prophylaxis for Non-Myeloablative Unrelated Donor Allogeneic Stem Cell Transplantation
1173
Thymic Recovery and De Novo T Cell Production During
the First Year After Unrelated Cord Blood Transplant (UCBT) Predicts Overall
Survival: A Multivariate Analysis of 93 Patients Following Myeloablative
Conditioning and a Single Unit Graft
Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster I
1174 Prevalence and Significance of Pre-Formed Anti-HLA Antibodies in Hematopoietic Stem Cell Transplant Recipients
1175 Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial
1176 Nilotinib Treatment Post - Allogeneic Stem Cell Transplantation (alloSCT) in Advanced (>CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
1177 Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma
1178 Comparable Outcomes with or without Routine Granulocyte Growth Factor Support Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Single Center Experience
1179 Influence of Glutathione S-Transferase (GST) Gene Polymorphisms On the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation
1180 Comorbidities Index Is Not Predictive of Treatment Related Mortality in Patients (pts) Older Than 60 Years Treated with Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (RIC-ALLO)
1181 Sustained Complete Metabolic Remission After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
1182 Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation
1183 Engraftment Kinetics After Transplantation of Double Units of Umbilical Cord Blood From Unrelated Donors in Adolescents and Adults with Hematologic Malignancies
1184 Unpredictable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination of Optimal Once-Daily Busulfan Dose Using Pharmacokinetic Modeling
Clinical Results - Allogeneic Matched Related Donor Transplantation Poster I
1185 Impact of Missing KIR Ligands in HLA-Matched Unrelated Donor HSCT
1186 Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma
1187 Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire
1188 Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Société Française De Greffe De Moelle-Thérapie Cellulaire (SFGM-TC)
1189 Clinical and Genetic Risk Assessment for Overall Survival in Haematopoietic Stem Cell Transplantation (HSCT)
1190 Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT
1191 TLR9 but Not NOD2/CARD15 Gene Polymorphism Influence Outcome in AML-Patients Transplanted From HLA-Identical Sibling Donors
1192 Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL)
1193 "Human Development Index" Correlates with Rates and Influences Outcome of Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia
1194 A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia
Clinical Results - Alternative Donor Transplantation Poster I
1195 "An Intention-to-Treat Analysis of Rome Transplant Network Policy for Alternative Donor Search in Patients Lacking a HLA Matched Related donor"
1196 Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation
1197 Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable to Unrelated Donor Transplantation for Patients with Hematologic Malignancies
1198 Unrelated Cord Blood Transplantation (UCBT) in Adults with MDS or Secondary Acute Myeloblastic Leukemia (sAML): a Survey On Behalf of Eurocord and CLWP of EBMT
1199 Allogeneic Hematopoietic Cell Transplantation in AML: Comparable Results After Matched or Mismatched Unrelated Versus Matched Related Transplantation
1200 The Prognostic Value of Residual FDG-Avidity Prior to Allogeneic Stem Cell Transplantation for Lymphoma
1201 Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma
1202 Impact of the Intensity of Conditioning Therapy On the Outcomes of Patients Aged 40 to 60 Years with Acute Myeloid Leukemia/Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation
1203 Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution
1204 Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma
1205 A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC
1206 The Impact of HLA Haplotype Matching for Mismatched Cord Blood Transplantation
1207 Fludarabine, Cyclophosphamide, Anti-Thymocyte Globulin, with or without " 2Gy TBI, for Alternative Donor Transplants in Acquired Aplastic Anemia (SAA): A Report From the EBMT-SAA Working Party
1208 Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Outcomes Are Not Impaired in Patients of Advanced Age
1209 Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation
1210 Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia
1211 Unrelated Cord Blood Transplantation in Patients with Hematologic Malignancies in Brazil – A Sociedade Brasileira De Transplantes De Medula Ossea and Eurocord Collaborative Study
1212 Long Term Survival After Sirolimus Based Non-Ablative Alternative Donor Transplantation
Experimental Transplantation - GVHD and GVL Poster I
1329 Quantification of WT1 Gene Expression for Minimal Residual Disease Detection as Predictor of Relapse in Patients with AML After Allogeneic Stem Cell Transplantation Compared to Flow Cytometry and Chimerism
1330 Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia
1331 Donor BM Dendritic Cells Expressing IDO Limit Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplant
1332 Memory CD8+ T Cells Specific for Minor Histocompatibility Antigen H60 Can Mediate the Graft-Versus-Leukemia Effect
1333 Induction of Potent Anti-Tumor Effects by Original and TCR-Redirected CD4+ Cytotoxic T Cells
1334 Rapamycin and IL-2 Prevents Lethal Acute Graft-Versus Host Disease by Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells
1335 P-Selectin in Recipients of Allogeneic Bone Marrow Transplantation Regulates Experimental Graft-Versus-Host-Disease
1336 ATP Acts as Danger Associated Molecular Pattern and Enhances Acute Graft-Versus-Host Disease Severity Via P2X7-R
1337 CCR1 Is Required for Treg-Mediated Protection From Lethal Acute Graft-Versus-Host Disease
1338 Galectin-9 Ameriorates Acute GVHD by Inducing T-Cell Apoptosis and Increasing Regulatory T Cell
1339 Activation of the Adenosine A2A Receptor Promotes the Development of Donor-Derived T Regulatory Cells in a Graft-Versus Host Disease Mouse Model
1340 Adoptive Transfer of Primed T Cells Mediates a Graft-Versus-Leukemia Effect against Pediatric ALL
1341 Regulatory T Cells Prevent Effector T Cell Infiltration Into GvHD Target Tissue by Affecting Chemokine Signaling
1342 Mutual Activation and Expansion of Donor CD4+ T Cells and B Cells in Transplants Play a Critical Role in the Initiation of Chronic Graft-Versus-Host Disease
1343 Hematopoietic Regeneration Is Suppressed by the GvHD Condition in a Haplo-Identical Bone Marrow Transplant Model
1344 Identification of Novel MHC Class II-Restricted Male-Specific mHAg Encoded by SMCY (JARID1D)
Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster I
1657 Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)
1658 Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
1659 Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma
1660 Aggressive Primary Chemotherapy Plus Autologous Stem Cell Transplantation Improves Outcome for Peripheral T Cell Lymphomas Compared with CHOP-Like Regimens
1661 The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL
1662 Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study
1663 Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain
1664 Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease
1665 A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma
1666 A Novel Bayesian Prognostic Index for Diffuse Large B-Cell Lymphoma: A New Powerful Tool for Prediction of Outcome
1667 Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma
1668 Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups
1669 A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma
1670 Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin’s Disease: Mature Results of the G4 Trial
1671 Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial
1672 High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL)
1673 A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)
1674 Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results
1675 Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
1676 Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin’s Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003)
1677 Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin’s Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods
1678 Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)
1679 R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
1680 Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data
1681 Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis
1682 Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
1683 Post-Renal Transplant De Novo Non-Skin Malignancies in Mycophenolate Mofetil- and Calcineurin Inhibitor-Based Immunosuppression
Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster I
1700 Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab
1701 Efficacy and Safety of Prophylactic Use of Darbepoetin Alfa in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results of the Interim Analysis of the LNH03-6B GELA Study
1702 Overall Survival (OS) Benefit of Rituximab Based Immunochemotherapy Followed by Post-Induction Treatment in Mantle Cell Lymphoma (MCL): a Retrospective Analysis of 279 Patients Treated by Polish Lymphoma Research Group (PLRG) Centers
1703 Feasability and Toxicity After Induction Treatment with Rituximab-HCVAD and Metotrexate/Citarabine, Followed by Consolidation with Y-90 Ibritumomab Tiuxetan (Phase II GELTAMO–LCM 04-02 study)
1704 Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL)
1705 Rituximab Infusion Induces NK Activation in Subjects with the High Affinity CD16 Polymorphism
1706 Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial
1707 Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study
1708 Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma
1709 The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden
1710 The Combined Safety and Tolerability Profile of Vorinostat-Based Therapy for Solid or Hematologic Malignancies
1711 Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies
1712 Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
1713 Salvage Treatment with Lenalidomide and Dexamethasone in Patients with Relapsed Refractory Mantle Cell Lymphoma
1714 A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster I
1914 Increased Activity of the S Phase Kinase Cdc7 Is Associated with Poor Outcome in Diffuse Large B Cell Lymphoma (DLBCL)
1915 RNA-Expression and Proteome Analysis Identify Complementary but Not Identical Molecular Targets in Enzastaurin-Treated Mantle Cell Lymphoma
1916 Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin’s Lymphoma Development and Survival
1917 Aberrant Overexpressions of MicroRNA-21 and MicroRNA-155 Activate AKT Signaling Via Downregulation of Tumor Suppressors in NK-Cell Lymphoma/Leukemia
1918 Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies
1919 TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis
1920 Trends in Human T-Cell Leukemia Virus Type-1 (HTLV-1) Prevalence and the Incidence of Adult T-Cell Leukemia/Lymphoma (ATL) in Nagasaki, Japan: A Hospital-Based and Population-Based Study
1921 Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma
1922 Frequent Expression of MUC1, a Membrane-Associated Mucin, in Adult T-Cell Leukemia Cells
1923 Flow Cytometry Study of CD148, a Tyrosine Phosphatase Receptor, in 184 Chronic B Cell Malignancies, Reveals a High Expression in Mantle Cell and Marginal Zone Lymphomas
1924 Histopathological EXAMINATION of BONE MARROW Biopsy (BMB) IN Primary Splenic B CELL Lymphomas of Marginal-ZONE ORIGIN (PSMZL). A Reliable Substitute for Spleen Pathology?
1925 Translation Regulatory Protein 4E-Binding Protein (BP)-1 Phosphorylation Identifies Diffuse Large B Cell Lymphoma Patients with Low IPI Scores Who Experience Short Survival After Chemotherapy
1926 Serum Interleukin-18 Level Determines Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma in Rituximab Era
1927 Clinico-Pathological Characteristics of B-Cell Non Hodgkins Lymphomas Associated with Hepatitis C Virus ANRS HC13 LYMPHO-C Observational Study
1928 DLEU1 siRNA Gene Knockdown IN BURKITT LYMPHOMA (bl) IS ASSOCIATED with A SIGNIFICANT Decrease IN Cyclophosphamide (CY) and/or Rituximab Induced Apoptosis: Mechanism of Drug Resistance in BL
1929 CD137 Expression Is Enhanced in EBV-Infected T or NK Cells by Viral Protein LMP1 and Mediates Anti-Apoptotic Intracellular Signaling through NF-κB Activation
1930 Lymphopenia Predicts Survival in Peripheral T-Cell Lymphoma, Unspecified
1931 Over-Expression of IDO in NHL Results in Conversion of CD4+CD25- T Cells Into CD4+CD25+ T Cells
1932 Inverse Relationship Between the Transcription Repressor Yin Yang 1 (YY1) and the TRAIL Death Receptor DR5 in AIDS-Related Non-Hodgkin’s Lymphoma Tissues: Potential Prognostic Biomarkers and Targets for Therapeutic Intervention
1933 Sequence-Based Evidence for Antigen Selection in Mantle Cell Lymphoma: Remarkable Immunoglobulin Gene Repertoire Biases, Stereotyped Antigen-Binding Sites and Recurrent Hypermutations in Certain Subsets
1934 Activation of PI3K/Akt/mTOR Pathway in Diffuse Large B-Cell Lymphomas: Clinical Significance and Inhibitory Effect by Rituximab
1935 Prognostic Importance of Soluble Form IL-2 Receptor α (sIL-2Rα) and Its Relationship with Surface Expression of IL-2Rα of Lymphoma Cell in Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy: a Retrospective Analysis of 409 Cases
1936 Prognostic Significance of Circulating Epstein-Barr Virus (EBV) DNA in Non-Hodgkin's Lymphoma
1937 PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM)
1938 Expression of the B-Cell Stimulatory Factors BAFF and APRIL in Gastric MALT Lymphomas
1939 Association of Genetic Polymorphisms of Glutatione-S-Transferase Genes and Overall Response/Clinical Features in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab
1940 The Role of JAK3 mutations in Adult T-Cell Leukemia/Lymphoma
1941 A Comparison of Gene Expression Pattern in Major Histocompatibility Class II-Low Diffuse Large B-Cell Lymphoma with Plasmablastic Lymphoma
1942 Diffuse Large B-Cell Lymphoma in the Very Elderly, a Study of Outcome in Patients Aged 80 and Older
1943 Identification of Genes Which Play a Crucial Role in C/EBPß Downstream Signalling in ALK+ ALCL Cell Lines
1944 High Risk of Hepatitis B Virus Reactivation in Isolated Anti-Hbc Positive Patients with B-Cell Lymphoma Receiving Rituximab Containing Chemotherapy
1945 T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis
1946 Predictors of Early Response to Single Agent Rituximab in Patients with Indolent Lymphoma
1947 IgA and IgG Hypogammaglobulinemia Does Not Predict for Recurrent Infection Risk and Persists Despite Therapeutic Response in Patients with Waldentrom’s Macroglobulinemia
1948 High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT)
1949 Prediction of MHC Class I-Restricted Immunogenic Epitopes of B-Cell Receptors Indicates T Cell-Mediated Immunosurveillance of Malignant B Cell Clones
1950 Activation of T- and NK- Cells through CD19xCD3 and CD19xCD16A Bispecific TandAb Antibodies in Patients with B-Cell Non-Hodgkin´s Lymphoma
1951 First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin’s Lymphoma (NHL)
1952 Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma
1953 CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas
1954 Impact of Socioeconomic Status & Race/Ethnicity On Survival in Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study
1955 Stimulation of B-Cell Mature Malignancies with the CpG-Oligonucleotide DSP30 and Interleukin-2 for Improved Detection of Chromosome Abnormalities
1956 Negative Interim FDG-PET Scan Is Predictive of Superior Outcome in T Cell Lymphoma
Clinical Results - Allogeneic Matched Related Donor Transplantation: Lymphoid Malignancies/Myeloma
49 Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis
50 Tandem Autologous-Allogeneic Nonmyeloablative Sibling Transplant in Relapsed Follicular Lymphoma Leads to Impressive Progression Free Survival with Minimal Toxicity
51 Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial
52 Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT
53 Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis
54 Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 – 2005
97 First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d’Etude Des Lymphomes De l’Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL)
98 Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab
99 Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP
100 Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial
101 Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d’Etude Des Lymphomes De l’Adulte
102 Non-Hodgkin Lymphoma in Adolescents: Experiences in 378 Adolescent NHL Patients Treated According to Pediatric NHL-BFM Protocols
103 Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors
104 Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group Report
105 Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome
106 Comparative Clinical and Biological Features of Primary Mediastinal B-Cell Lymphoma (PMBL) and Mediastinal Grey Zone Lymphoma (MGZL)
107 Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens
108 First Line Antiviral Therapy Significantly Improves Survival of Patients with Acute, Chronic and Smoldering ATL: a Worldwide Meta-Analysis
133 HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy
134 Follicular PD-1+ Lymphocytes in the Tumor Microenvironment Are An Independent Prognostic Factor in Follicular Lymphoma
135 Prospective Measurement of EBV-DNA in Plasma and Peripheral Blood Mononuclear Cells of Extranodal NK/T-Cell Lymphoma, Nasal Type
136 Elevated Pre-Treatment Serum Immunoglobulin Free Light Chains (FLC) Are Associated with Poor Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL)
137 PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
138 Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort
Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster II
2266 A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab
2267 Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial
2268 Cyclophosphamide-Busulfan Instead of Busulfan-Cyclophosphamide for Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation
2269 Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 and Acute Graft-Versus-Host Disease After Allogeneic Hematopietic Cell Transplantation with Nonmyeloablative Conditioning
2270 Fludarabine-Associated Neurotoxicity After Hematopoietic Cell Transplantation (HCT): Clinical and Radiographic Features Predict Outcome
2271 High-Dose Melphalan Re-Induction with or without Stem Cell Support Prior to Myeloablative Allogeneic Stem Cell Transplantation in Patients with Advanced Relapsed or Refractory Acute Myeloid Leukemia
2272 Low Dose Subcutaneous Alemtuzumab and Prophylactic Donor Lymphocyte Infusion Results in Favorable Outcomes for High Risk Recipients of Unrelated Donor Allogeneic Transplants
2273 Optimization of Fludarabine + Melphalan Conditioning for Marrow Transplantation From Unrelated Donors for Patients with Hematopoietic Malignancies: A Prospective Dose-Finding Trial Using Modified Continual Reassessment Method
2274 Pegfilgrastim Accelerates Neutrophil Engraftment, Reduces the Number of Neutropenic and Hospitalization Days and the Use of Antibiotics After Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma and Lymphoma. A Phase II Study and Comparison with a Filgrastim Treated Historical Cohort
2275 Pegfilgrastim Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay
2276 Pharmacokinetics of Mycophenolic Mofetil and Metabolites in Allogeneic Transplant: Determination of Maximum Dose Schedule and Route of Administration
2277 Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization
2278 The Effect of Obesity On Outcome of Unrelated Cord Blood Transplant in Children with Malignant Diseases
2279 The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients
2280 The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation
Clinical Results - Allogeneic Matched Related Donor Transplantation Poster II
2281 A Markov Decision Analysis of Post-Remission Strategies in 2029 Patients with AML in First Remission (CR1): Should We Perform Allogeneic Hematopoietic Cell Transplantation in CR1?
2282 A Reduced Rate of Leukaemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukaemia but Not Other Haematological Malignancies Is Associated with Donor KIR Genes 2DL5A, 2DS1 and 3DS1
2283 Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis
2284 Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients
2285 First Interim Analysis of HOVON 76: Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma
2286 High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry
2287 Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL)
2288 Long-Term Outcome of Children with Acute Myeloid Leukemia in First Remission Given Allogeneic HSCT from a Matched Family Donor After a Conditioning Regimen Comprising Busulfan, Cyclophosphamide and Melphalan
2289 Proportion of Adult AML Patient Population Receiving Allogeneic Stem Cell Transplantation and Long-Term Outcome: Real World Data From the Swedish National Acute Leukemia Registry
2290 Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia
Clinical Results - Autologous Transplantation Poster II
2309 A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma
2310 Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
2311 Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study
2312 Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
2313 Comorbidity at Relapse Is An Independent Predictor for Eligibility and Outcome of Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma
2314 High Dose Chemotherapy and Autologous Stem Cell Transplantation in the Primary Therapy of Advanced Follicular Lymphoma in Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
2315 Higher Incidence of Relapse with Higher Doses of CD34+ Cells From Leukapheresis Products Infused in Adults with Acute Myelocytic Leukemia Autografted During the First Remission
2316 Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL)
2317 Reduced Intensity Conditioning Regimens in Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis patients
2318 Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis
2319 Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization
2320 Single Versus Tandem High Dose Therapy (HDT) Supported with Autologous Blood Stem Cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC: Long-Term Results of a Two by Two Designed Randomized Trial in 225 Young Patients with Multiple Myeloma (MM). for the Group "Myelome-Autogreffe", Caen, Creteil, Limoges, Paris, Strasbourg, France
2321 Status of Minimal Residual Disease Determines Outcome of Autologous HSCT in Adults with High-Risk Acute Lymphoblastic Leukemia
2322 Two Cycles of PAD Combination (PS-341/ Bortezomib, Adriamycin and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation (AHCT) in Newly Diagnosed Multiple Myeloma (MM) Patients
2323 Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL)
Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster II
2679 Peripheral Blood Stem Cell Mobilization After Bendamustine Containing Chemotherapy in Indolent Lymphomas Is Possible. Results From the Phase III Study of B-R Vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany)
2680 A Non-Radiation-Containing, Intermediate-Dose Methotrexate (MTX) Regimen Resulted in Favorable Survival without Progression of Dementia in Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL)
2681 Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma: A Pooled Analysis
2682 CHOP-R + Bortezomib as Initial Therapy for Mantle Cell Lymphoma (MCL)
2683 Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement
2684 Comprehensive Geriatric Assessment-Adapted Chemotherapy in Elderly Patients (>70 years) with Diffuse Large B-Cell Non-Hodgkin’s Lymphoma (DLBCL): Final Results and Long Term Follow-up
2685 Efficacy of a Brief, Cyclophosphamide-Intensive Regimen for Older Patients with Newly Diagnosed Burkitt's or Atypical Burkitt's Lymphoma/Leukemia
2686 Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Update of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324)
2687 How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial)
2688 Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma
2689 Long-Term Outcomes of Patients with Newly Diagnosed NK/T-Cell Lymphoma Treated by EPOCH Regimen
2690 Low-Intensity Fludarabine, Cyclophosphamyde, Rituximab (FCR) as Front-Line Treatment for Follicular Lymphoma. Efficacy and Toxicity Profile of the Oral Versus Intravenous Administration
2691 Outcome of Second Line Therapy for Pediatric Patients with Hodgkin Lymphoma Who Relapse Following ABVD Based Therapy
2692 Pegylated Liposomal Doxobubicin (PLD) Can Be Escalated in a Dose-Dense, 14 Day CDOP-Rituximab Regimen without Affecting Relative Dose Intensity (RDI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Are Elderly or Have Compromised Cardiac Status
2693 Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052
2694 Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with Primary Central Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial
2695 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL trial): Correlation between Clinical Variables and PET Parameters
2696 Post-Chemotherapy Brain Irradiation in Primary CNS Lymphomas: Impact on Survival of Different Fields and Doses
2697 Primary Testicular Diffuse Large B-Cell Lymphoma, M.D. Anderson Cancer Center Experience
2698 Risk Factors for Early Transformation of Follicular Lymphoma (FL): Report From the National LymphoCare Study (NLCS)
2699 Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Who Had Received Prior Stem Cell Transplant
2700
The Impact of Outcome and Hepatic Toxicity in
HCV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab
Plus CHOP Therapy; A Retrospective Multicenter Japanese Analysis
2701
Title:Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R)
in Untreated Patients with Poor Risk Large B-Cell Lymphoma. A Phase 2 Study
Conducted by the Spanish PETHEMA Group
2702
Treatment of Primary CNS Lymphoma in the Elderly with
High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or
Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment
Modalities in Leon Berard Cancer Center
2703
Validation of the Mantle Cell Lymphoma Prognostic Index
(MIPI): A Valuable Tool for Risk Stratification in Mantle Cell Lymphoma Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents
Poster II
2704
Anti-CD20 Antibody GA101 Shows Higher Cytotoxicity but
Is Competitively Displaced by Rituximab in Mantle Cell Lymphoma
2705
Conventional and Pretargeted Radioimmunotherapy with
Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A
Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual
Disease
2706
Enhancing Natural Killer (NK) Cell Mediated Killing of
Non-Hodgkin’s Lymphoma
2707
GA101-Coated Target Cells Are More Effective Than
Rituximab-Coated Target Cells at Activating NK Cells When Complement Is Present
2708
Glutathione Depletion Enhances Arsenic
Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and
Caspase-Independent Mechanisms
2709
In-Vitro and in-Vivo Evaluation of the Orally Active
Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer
2710
Mitochondrial-Mediated Apoptosis in Lymphoma by the
Diterpenoid Lactone Andrographolide (Andro), the Active Component of
Andrographolis Paniculata
2711
Multivalent DNA Aptamer-Based Therapeutic Agents for
Lymphoma and Leukemia
2712
Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine
for B-Cell Lymphoma
2713
PX-478, a Novel Small Molecule Inhibitor of Hypoxia
Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in
Diffuse Large B Cell Lymphoma Cells
2714
The Combination of Arsenic Trioxide and
Interferon-Alpha Eradicates Leukemia Initiating Cells in TAX-Driven Murine
Adult T Cell Leukemia/Lymphoma
2715
The DAC Inhibitor, LBH589, Is Highly Effective in Both
Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the
Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20
Monoclonal Antibodies
2716
Therapeutic Antibody Targeting of CD47 Synergizes with
Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts
2717
Treatment with the CXCR4 Antagonist AMD3100 Enhances
Antibody Mediated Killing in Disseminated Lymphoma Models
2718
YM155, a Novel Survivin Suppressant, Improves the
Antitumor Effect of Rituximab and Rituximab-Containing Regimens in Diffuse
Large B Cell Lymphoma (DLBCL) Xenograft Mouse Models Lymphoma: Therapy with Biologic Agents,
excluding Pre-Clinical Models Poster II
2720
A Phase II Trial of Rituximab-CHOP Chemotherapy
Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (90Y-IT) for Previously
Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients
2721
CD40 Pathway Activation Status Predicts Response to
CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma
2722
Clinical Outcome of Patients with Follicular Lymphoma
and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without
Consolidating Radiotherapy
2723
Confirmation of Safety, Efficacy and Response Duration
in Non-Hodgkin Lymphoma Patients Treated with 60 µg/m²/d of BiTE® Antibody
Blinatumomab
2724
Molecular Remission after Induction Chemo-
Immunotherapy and Rituximab Maintenance in Previously Untreated Follicular
Lymphoma
2725
Multicenter Phase II Study of the CyclOBEAP Plus
Rituximab in Diffuse Large B-Cell Lymphoma with Analysis of Biomakers
2726
Phase I Analysis of the Safety and Pharmacodynamics of
the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in
Relapsed and Refractory Lymphoma
2727
Phase II Trial of Weekly Bortezomib in Combination
with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom’s
Macroglobulinemia
2728
Response Is Seen to Conjugate Vaccine but Not to
Polysaccharide Vaccine Twelve Months After Rituximab
2729
Sunitinib in Relapsed or Refractory Diffuse Large B
Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical
Trials Group
2730
Sustained, Durable Responses with Alemtuzumab in
Refractory Angioimmunoblastic T-Cell Lymphoma
2731
The Antibody-Drug Conjugate Brentuximab Vedotin
(SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or
Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study
2732
Tositumomab and Iodine I-131 Tositumomab (Bexxar®
therapeutic regimen) for Non-Hodgkin’s Lymphoma Patients Who Progressed After
Treatment with Rituximab: Long Term Follow-up of a Multi-Center Phase II Study Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster
II
2918
Risk of Hepatitis B Virus (HBV) Reactivation and
Efficacy of Antiviral Preemptive Therapy in Malignant Lymphoma Patients Who
Have Resolved HBV
2919
Cerebrospinal Fluid Flow Cytometry Analysis in Newly
Diagnosed Aggressive Non-Hodgkin Lymphomas at High Risk for Leptomeningeal
Disease: Result of a Multicentric Prospective Italian Study
2920
Proposal of Progressive Adult Onset EBV-Associated
Lymphoproliferative Disorder (PAEBV) as a Rapid-Onset Neoplastic Disease
2921
Patterns of Outcome Following Recurrence in Patients
with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre
2922
Chromosomal Alterations in Gene Expression-Defined
Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL)
2923
The Percentage of Cytotoxic T-Cells in Mantle Cell
Lymphoma (MCL) Biopsies Predicts Response to Rituximab
2924
The Immunohistochemical Pattern of Indoleamine
2,3-Dioxygenase in Tumor Tissue Indicates the Prognosis of Patients with
Diffuse Large B-Cell Lymphoma
2925
Nuclear Expression of the Sox 11 Transcription Factor in
Mantle Cell Lymphoma, and Cytoplasmic Expression in Follicular Lymphoma
and Multiple Myeloma: Pathogenetic Implications
2926
Waldenstrom's Macroglobulinemia: A SEER Database
Review From 1981-2005
2927
Levels of sIL-2R in Sera Depend On Number of
CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL
2928
Mantle Cell International Prognostic Index (MIPI) Is a
Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab
(R) Era
2929
MicroRNAs Are Differentially Expressed in Primary
Central Nervous (CNS) and Nodal Diffuse Large B-Cell Lymphomas
2930
''CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic
cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of
Immunohistochemical Markers and Poor Outcome.''
2931
The 18F-FDG SUVmax Reduction After Two Cycles of
R-CHOP Regimen Predicts Progression Free Survival of Patients with Diffuse Large
B-Cell Lymphoma
2932
P52 Activation in Monomorphic B-Cell Post-Transplant
Lymphoproliferative Disorders without BAFF-R Expression
2933
Diagnostic Plasma-Derived Proteomic Biomarkers of
Aggressive Diffuse Large B-Cell Lymphoma: Preliminary Data Based On the 075
French GEOLAMS Multicentric and Prospective Trial
2934
Clinical and Biological Implications of Hepatitis C
Virus Positivity in Waldenstrom’s Macroglobulinemia Patients
2935
Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in
Waldenstrom’s Macroglubulinemia and Plays a Major Role in Its Interaction with
the Bone Marrow Microenvironment
2936
Integrative Analysis of MicroRNA and Gene Expression
Profiling Contributes to Understand Mantle Cell Lymphoma Pathogenesis
2937
The Type of Enteropathy Is a Prognostic Factor in
Enteropathy-Associated T-Cell Lymphoma
2938
Two Distinct Syndromes of Lymphoma-Associated
Amyloidosis: Findings From a Case Series
2939
SIGNIFICANCE of ABSOLUTE LYMPHOCYTE COUNT at RELAPSE
as a PROGNOSTIC FACTOR in PATIENTS with T-CELL NON-HODGKIN’S LYMPHOMA
2940
Central Nervous System Involvement in Primary
Nasal Lymphoma
2941
PTEN Regulates SYK-Directed AKT Activation in MCL
2942
Detection of LMO2 in Normal Human Tissues and
Haematopoietic and Non-Haematopoietic Tumours by a Newly Developed Rabbit
Monoclonal Antibody
2943
Genomic and Transcriptomic Analyses Revealed
Differences and Similarities Between T-Lbl and T-ALL
2944
Minimal Disseminated Disease Is An Indipendent Poor
Prognosis Marker Among High Risk Burkitt’s Lymphoma Patients
2945
High-Throughput Analysis of Antigen Recognition by the
B Cell Receptors of Malignant Lymphomas with High-Density Protein Microarrays
2946
Involvement of Ets Factor Spi-B, E Protein E2-2, and
Id2 in Waldenström’s Macroglobulinemia
2947
"Prognostic Significance of Circulating Lymphoma
Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)."
2948
Detailed Phenotypic Characterization of T-Cell
Populations in Reactive, Normal and Follicular Lymphoma Nodes: Elevation of
Follicular B Helper T-Cell Subsets in Follicular Lymphoma
2949
Polymorphisms of FcγRIIA, FcγRIIB, and
FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in
Patients with Waldenstrom’s Macroglobulinemia
2950
Micro-RNA Expression Profiling Reveals Distinct
Correlates to Disease Pathogenesis, and Identifies Novel Pathways Involved in
Tumor Cell Senescence and IL-12A Signaling
2951
Gene Expression Signature of Host Immune Response Is
Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and
Correlates with Transformation to Diffuse Large B-Cell Lymphoma
2952
Patients with Waldenstrom’s Macroglobulinemia Are
Often Hypoferremic That Is Refractory to Oral Iron Repletion and Responsive to
Parental Iron Infusions, and Demonstrate Elevated Levels of Hepcidin
193
Prospective Randomized Comparison of Reduced Intensity
(FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical
Allo-SCT: a Clinical and economical Multicenter Itac Study
194
Reduced-Intensity Conditioning (RIC) Allogeneic Stem
Cell Transplantation (allo-SCT) for Patients Aged ≥60 Years: a
Retrospective Study of 629 Patients From the Societe Française De Greffe De
Moelle Et De Therapie Cellulaire (SFGM-TC)
195
Comparison of Outcomes After Allogeneic HSCT for Adult
Patients with AML in Remission Using in the Conditioning Regimen Either I.V.
Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An- ALWP-EBMT Survey
196
Reduced-Intensity Conditioning with FBA/FBAA Regimen
Is Feasible for Allogeneic Hematopoietic Stem Cell Transplantation for Acute
Myeloid Leukemia (AML): Interim Results of a Multicenter Clinical Trial in
China
197
Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab
(CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in
Patients with Advanced Hematologic Malignancies: Determination of MTD and
Outcomes
198
Phase I Trial of High-Dose Clofarabine and Busulfan as
a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell
Transplantation in Patients with Relapsed or Refractory Acute Leukemia
314
Epstein Barr Virus Micrornas Repress BCL6 Expression
in Diffuse Large B Cell Lymphoma
315
Targeting of SMAD5 Links MicroRNA-155 to the TGFβ
Pathway and Lymphomagenesis
316
HGAL, a Lymphoma Prognostic Biomarker, Regulates
Lymphocyte and Lymphoma Cell Motility by Modulation of RhoA Signaling Pathway
317
Evidence for Antigen-Driven Development of Molecularly
Classified Burkitt Lymphomas
318
Non Germinal-Center B Cell Like Diffuse Large B Cell
Lymphoma Results From Repeated Activation of IgM B Cells That Resist
Class-Switching
367
Mobilization Studies in Complement-Deficient Mice
Reveal That AMD3100 Mobilization Depends On Complement Cascade Activation and
Suggest Involvement of “Membrane Attack Complex - MAC” in Egress of
Hematopoietic Stem/Progenitor Cells
368
Plerixafor (Mozobil®) Selectively Enhances Donor
Hematopoietic Cell Engraftment
369
Human Umbilical Cord Blood Stem Cell Function Is
Augmented by Exposure to Prostaglandin E2
370
In Vivo Treatment with Chromatin Modifying Agents
Dramatically Increases Hematopoietic Stem Cell Numbers
371
Granulocyte-Derived Cationic Peptides (GDCPs) Present
in Leucophoresis Products Enhance Homing of Hematopoietic Stem Cells (HSCs) to
SDF-1 Gradient; Potential Implications for Accelerated Recovery of
Hematopoiesis After Transplantation of Mobilized Peripheral Blood Stem Cells
(PBSC)
372
Use of the CD26 Inhibitor Diprotin A (Ile-Pro-Ile) to
Increase Mobilized Peripheral Blood Mononuclear Cell Adhesion and Migration Lymphoma: Chemotherapy, excluding Pre-Clinical Models -
Non-Hodgkin Lymphoma: Therapy
404
Aggressive Chemotherapy (CHOEP-14) and Rituximab or
High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with
Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High –
Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
405
Bendamustine Plus Rituximab Is Superior in Respect of
Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as
First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle
Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL
(Study Group Indolent Lymphomas, Germany)
406
R-CHOP14 Compared to R-CHOP21 in Elderly Patients with
Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B
GELA Study
407
Bortezomib Added to CVP-R Is Safe and Effective for
Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study
by the NCIC Clinical Trials Group
408
R-CHOP with Etoposide Substituted for Doxorubicin
(R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with
a Contraindication to Anthracyclines Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Genetic
Factors in Lymphoma
439
Base-Pair Resolution of Somatic and Germline-Derived
Genome Rearrangement Breakpoints in Follicular Lymphoma
440
Germline Variation in Complement Genes and Event-Free
Survival in Follicular Lymphoma
441
Quantitative Real-Time PCR of Peripheral Blood
t(14;18) Positive Cells Predicts Treatment Response and Long-Term Outcome in
Patients with Follicular Lymphoma
442
The Host Genetic Background of DNA Repair Mechanisms
Represents An Independent Predictor of Progression and Survival in Diffuse
Large B-Cell Lymphoma Treated with R-CHOP
443
MYC Translocations Are Associated with Poor Overall
Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras
444
SNP-Arrays Provide New Insights Into the Pathogenesis
of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL)
511
Selecting Haploidentical Transplant Donors for
Deploying Optimal NK Cell Allotherapy
512
Haploidentical Stem Cell Transplantation: High Doses
of Alloreactive-T Cell Depleted Donor Lymphocytes Administered Post-Transplant
Decrease Infections and Improve Survival without Causing Severe Gvhd
513
Adoptive Transfer of Umbilical Cord Blood
(UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative
Unrelated Double UCB Transplantation
514
Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has
Diagnostic and Prognostic Value as a Biomarker for Acute Graft-Versus-Host
Disease
515
Allografts Selectively Photodepleted of GvHD Causing T
Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve
Disease Control After HLA-Matched Sibling Transplantations
516
Low Absolute CD4 Central Memory Count On Day 30 Is
Associated with An Increased Incidence of Chronic Graft-Versus-Host Disease Clinical Care, Recurrence, Secondary Neoplasia and Late
Complications After Transplantation II
517
Population-Based Analysis of Late Cardiovascular
Morbidity and Hospitalizations After Hematopoietic Cell Transplantation
518
Long-Term Survival and Late Events After Allogeneic
Stem-Cell Transplantation with Reduced-Intensity Conditioning (RIC) for AML and
Mds; Comparable Results with Myeloablative Conditioning
519
Male Gender, Quality of Grafted Cells, Advanced Age,
Rituximab and Radiotherapy Are the Main Factors That Variously Influence the
Occurrence of Secondary Malignancies Following High-Dose Therapy and
Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in
1,347 Lymphoma Patients
520
Long-Term Survival and Late Deaths in 2-Year Survivors
of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic
Disorders
521
Neurocognitive Function and Its Impact On Return to
Work in Patients Treated with Hematopoietic Cell Transplantation (HCT)
522
Development of Psycho-Intellectual Performances of
Transplanted Sickle Cell Disease Patients: a Prospective Study From
Pre-Transplant Period to 5 Years After HSCT
583
IPH1101, the First Specific γδ T Cell
Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular
Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study
584
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin
(CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with
Recurrent/Refractory Follicular or ‘Aggressive’ Lymphoma
585
Phase I Multi-Dose Escalation Study of the Anti-CD19
Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion
Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin’s
Lymphoma (NHL)
586
A Phase 1b Clinical Trial of Dacetuzumab in
Combination with Rituximab and Gemcitabine: Multiple Responses Observed
in Patients with Relapsed Diffuse Large B-Cell Lymphoma
587
A Phase II Trial of the Oral mTOR Inhibitor Everolimus
(RAD001) in Relapsed or Refractory Waldenstrom’s Macroglobulinemia
588
Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518
in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity
619
ABC and GCB DLBCLs Display Unique Biologically
Distinct and Clinically Relevant Epigenetic Signatures
620
Accurate Classification of Diffuse Large B Cell
Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease
Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From
the Lymphoma and Leukemia Molecular Profiling Project
621
Molecular Profiling Identifies Plasmablasts as the
Cells of Origin of Activated Diffuse Large B Cell Lymphoma
622
Prediction of Survival in Diffuse Large B-Cell
Lymphoma Based On the Expression of Two Genes: Integration of Tumor and
Microenvironment Contributions
623
Classification of Newly Diagnosed Diffuse Large B-Cell
Lymphoma (DLBCL) According to the Han’s Criteria Defines Two Groups of Patients
with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent
Anthracycline-Based Therapy
624
MicroRNA Are Useful Biomarkers for Prediction of
Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma Clinical Results - Alternative Donor Transplantation II
661
Re-Exposure of Cord Blood (CB) to Non-Inherited
Maternal HLA Antigens (NIMA) Improves Transplant Outcome in Patients (pts) with
Hematologic Malignancies and May Reduce Relapse
662
Reduced Relapse and Similar Progression-Free Survival
After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of
Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem
Cell (HSC) Donors
663
Comparison of Outcomes After Unrelated Cord Blood
Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid
Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic
Leukemia Working Party of the European Group for Blood and Marrow
Transplantation Study
664
Comparison of Outcomes of Mismatched Related Stem Cell
and Unrelated Cord Blood Transplants in Children with Severe T-Cell
Deficiencies
665
Selection of Donors with Favorable KIR B Genotypes for
Unrelated Hematopoietic Cell Transplantation Results in Superior Relapse
Protection and Better Relapse-Free Survival for Patients with AML
666
Rapamycin-Based GvHD Prophylaxis Is Effective in
T-Cell Replete Unmanipulated Haploidentical Peripheral Stem Cell
Transplantation for Advanced Haematological Malignancies: Results in 46
Patients Non-Hodgkin's Lymphoma - Biology, excluding Therapy:
Indolent Non-Hodgkin's Lymphoma: Biology
757
Follicular Lymphoma Cell Niche: Identification of a
Preeminent IL-4-Dependent TFH- B Cell Axis
758
Increased Proportions of CD39+ Infiltrating T-Cells
Contribute to Adenosine Mediated T-Cell Hypo-Responsiveness within Human
Follicular Lymphoma
759
A Subpopulation of Follicular Lymphoma Tumor
Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling
760
Stereotyped Patterns of HCDR3 Sequences in Splenic
Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a
Worse Outcome
761
The IgM Flare Following Rituximab and IVIG
Administration in Waldenstrom’s Macroglobulinemia Is Related to IL-6 Production
by Bystander Immune Cells, Possibly through Stimulation of the Fcgriia Receptor
762
Genome Wide Association Studies of Familial
Waldenstrom's Macroglobulinemia (WM) Reveals a Loss of GSTM1 Is Common in
Families with a History of B-Cell Disorders but Not in Those with a History
Specific for WM
3304
A Dose Escalation Trial of Imatinib for Steroid
Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis
3305
Allogeneic Stem Cell Transplantation (allo-SCT) for
Secondary Acute Myeloid Leukemia (AML) Following Breast Carcinoma
3306
Antithymocyte Globuline Given as Part of the
Conditioning Regimen Has No Impact On Lung Function at 1 Year After Transplantation
3307
Comparison of Outcomes Between 2-Year Survivors After
Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem
Cell Transplantation
3308
Cryopreserved G-CSF Mobilized Donor Lymphocyte
Infusion (DLI) without Withdrawal of Immunosuppression Is Safe and Highly
Effective for Treating Isolated Poor Donor T-cell Chimerism
Following Reduced Intensity Allogeneic Transplantation (RICT)
3309
Donor Lymphocyte Infusions (DLI) After Peripheral
Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by
the Chronic Leukemias Working Party EBMT
3310
Donor Lymphocyte Infusions and Rituximab Are An
Effective Treatment Strategy for B-Cell Lymphoma Relapsing After Reduced
Intensity Allogeneic Stem Cell Transplantation
3311
Efficient Selection of WT1-Specific Donor Lymphocytes
by Streptamer Technology
3312
Favorable Outcome and Quality of Life in Patients Surviving
5 or More Years After Allogeneic Hematopoietic Stem Cell Transplantation for
Hematologic Malignancies
3313
Graft-Versus-Leukemia (GVL) Effect After Reduced
Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as
Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia
Working Party of the EBMT
3314
High Prevalence of Dapsone-Induced Oxidant Hemolysis
in North American Stem Cell Transplant Recipients without Glucose-6-Phosphate-Dehydrogenase
Deficiency
3315
Home Telemetric Monitoring of Pulmonary Function After
Allogeneic Hematopoïetic Stem Cell Transplantation: Results of a Prospective
Study Including 120 Patients
3316
Immune Reconstitution and Clinical Outcome After Donor
Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic
Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic
Myelogenous Leukemia
3317
Immunological Intervention Triggered by Decreasing
CD34+ Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid
Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic
Stem Cell Transplantation (HSCT)
3318
Impact On Survival and Treatment of Late-Onset
Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell
Transplantation
3319
Incidence and Characterization of Taste Disturbances
After Allogeneic or Autologous Hematopoietic Stem Cell Transplantation Using
Myeloablative or Reduced-Intensity-Conditioning
3320
Long-Term Survival and Late Deaths After Hematopoietic
Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn
Errors of Metabolism
3321
Long-Term Survival and Late Relapse in 5-Year
Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic
Myeloid Leukemia (CML) in First Chronic Phase
3322
Low Vitamin D Levels After Allogeneic Hematopoietic
Stem Cell Transplant
3323
Myeloablative Second Transplants Are Associated with
High Non-Relapse Mortality and Poorer Survival Than Non-Myeloablative
Second Transplants
3324
Nephrotic Syndrome After Allogeneic Hematopoietic
Cell Transplantation: Incidence and Outcomes
3325
Non-Relapse Mortality Exceeds Relapse Mortality Six
Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell
Lymphoma
3326
Phase-2 Study of Pomalidomide in Advanced
Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD)
3327
Prognostic Factors On Outcome of Mantle Cell Lymphoma
Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation
3328
Shift to a New Donor Does Not Improve the Outcome
After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia
Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell
Registry (DRST)
3329
Total Body Irradiation (TBI) Increases
Cardio-Metabolic Risk and Induces Carotid Vascular Stiffness in Survivors After
Hematopoietic Cell Transplant (HCT) for Childhood Hematologic Malignancies
3330
Vaccinations Efficacy in Long Term Survivors After
Allogeneic Stem Cell Transplantation: Implication of Repeat Vaccinations and
Documenting Vaccination Efficacy Clinical Results - Allogeneic Matched Related Donor
Transplantation Poster III
3356
12 Years Experience in Peru with Related Allogeneic
Stem Cell Transplantation (allo-sct) in Children with High Risk ALL
3357
90y-Ibritumomab Tiuxetan (Zevalin®) May Enhance
Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in
Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing
Allogeneic Hematopoietic Cell Transplant (Allo-HCT)
3358
Allogeneic Hematopoietic Stem-Cell Transplantation
Using Fludarabine/Treosulfan Conditioning Regimen Compared with Busulfan-Based
Myeloablative and Reduced-Intensity Conditioning in Patients with AML and Mds;
Relative Outcomes Depend On Disease Status at Transplantation
3359
Allogeneic Hematopoietic Stem-Cell Transplantation
with Reduced-Intensity Conditioning in Patients with Refractory and Relapsing
Multiple Myeloma: Long-Term Follow-up
3360
Autologous and Allogeneic Stem Cell Transplantation
for Richter’s Transformation: A Retrospective Analysis From the Chronic
Leukaemia Working Party and Lymphoma Working Party of the EBMT
3361
Bone Marrow Transplantation From HLA-Identical Sibling
for Thalassemia
3362
Comparative Analysis of Sibling Donor Reduced
Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte
Globulin Versus Alemtuzumab for T-Cell Depletion
3363
Comparison of Allogeneic Stem Cell Transplantation and
Best Supportive Care in Elderly Patients with Advanced MDS
3364
Comparison of Busulfan and Cyclophosphamide
(Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and
Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to
Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling
Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission
(CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia
Working Party of EBMT
3365
Estimating the Causal Effect of Some Exposure From
Nonrandomized Studies: The Example of Reduced Intensity Conditioning (RIC) in
Hematological Diseases
3366
First Line Allogeneic Stem Cell
Transplantation in Mantle Cell Lymphoma (MCL)
3367
Graft Versus Host Disease Correlates with Increased
Survival After Allogeneic Stem Cell Transplant for Mature T-Cell Lymphomas:
Evidence of Graft Versus T-Cell Lymphoma Effect
3368
Long Term Follow-up of Recipients of Combined
HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for
Multiple Myeloma with End-Stage Renal Disease
3369
Long-Term Complete Responses to Combination Therapies
in Sézary Patients
3370
Long-Term Outcome of ATL Patients Who Underwent
Reduced-Intensity Stem Cell Transplantation (RIST): Suggested Potent
Graft-Versus-ATL and HTLV-1 Effects
3371
Prospective Phase II Study of Pre-Administration of
Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®) to Maximize Early
T-Cell Chimerism Following Allogeneic Reduced Intensity Conditioning Transplant
(RICT) through Differential in-Vivo Depletion of Recipient Versus Donor
T-Cells
3372
Retrospective Monocentric Study of Patients with
Refractory Hodgkin Lymphoma: Allogeneic Stem Cell Transplantation (alloSCT)
Compared to Conventional Treatment Using the Propensity Score Matching Method
3373
Role of Gene Mutations in Adult Acute Myeloid Leukemia
Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
3374
The Association of Fludarabin, Oral Busulfan and
Thymoglobulin Prior to Matched-Related Allo-SCT Allows for High Long Term Outcome
for Both Patients with Myeloid or Lymphoid Malignancies and Reveals the Impact
of CD34+ Graft Cell Dose On Cgvhd and Outcome: Long Term Analysis of a
Homogenous Cohort of 100 Consecutive Patients
3375
The Role of In Vivo T-Cell Depletion On Reduced
Intensity Conditioning Allogeneic Hematopoietic Cell
Transplantation From HLA-Identical Siblings in Patients with Follicular
Lymphoma: An European Blood and Marrow Transplantation Study Clinical Results - Autologous Transplantation Poster III
3400
Achievement of CR and nCR Before and After First
High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major
Marker for Long-Term Survival in Multiple Myeloma Patients
3401
Prospective Phase II Study Using Dexamethasone
Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous
Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis
3402
A Phase I Trial of High-Dose Clofarabine, Etoposide,
and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous
Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or
Refractory Non-Hodgkin’s Lymphoma
3403
A Phase II Study of Sequential Velcade/Thalidomide/
Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral
Stem Cell (PSCT) in Patients with Multiple Myeloma
3404
An Outcome Study On Survival and Disease Control in
Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with
High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by
Post-Transplant Maintenance with Bortezomib and Lenalidomide
3405
Autologous Hematopoietic Cell Transplantation as
Consolidation for Younger Patients with Acute Myeloid Leukemia in First
Complete Remission: Follow-up of E1900
3406
Autologous Hematopoietic Stem Cell Transplantation
Following a Uniform Modified BEAM Conditioning Regimen for Hodgkin's
Lymphoma – Prognostic Factors and Long-Term Outcomes
3407
Autologous Stem Cell Transplant in Recurrent Diffuse
Large B- Cell Lymphoma: Prior Rituximab Therapy Has No Impact On Early
Lymphocyte Recovery and Transplant Outcome
3408
Combination of Bortezomib and Dexamethasone (VD) or
Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy
and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of
T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group
3409
Elderly Multiple Myeloma (MM) Patients (≥70
years) Can Safely Undergo Autologous Stem Cell Transplantation (ASCT) but Have
Shorter Overall Survival Than Younger Patients (<70 years)
3410
Febrile Neutropenia, Mucositis and Duration of
Hospitalization Are Reduced After Pegfilgrastim Following Autologous Peripheral
Blood Stem Cell Transplantation (PBSCT) for Malignant Lymphopathies: Report of
683 PBSCTs From a Single Institution
3411
High CD34 Yield Not Impaired by Melphalan 10mg/m2
Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total
Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly
Diagnosed Multiple Myeloma (MM)
3412
High Dose Cyclophosphamide (HD CY) without
Hematopoietic Stem Cell Transplantation (HSCT) in Refractory Severe
Autoimmune Diseases: 11 Year Experience in Over 100 Patients
3413
Initial Remission Duration of Less Than 1 Year Is No
Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing
High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined
Analysis From Two Large Transplant Centers
3414
Interim Restaging FDG-PET/CT to Guide Use of High Dose
Sequential Induction Therapy with Rituximab-Dose-Intensive Cyclophosphamide,
Etoposide, Cisplatin (RDICEP) and Rituximab-Carmustine, Etoposide, Cytarabine,
Melphalan (RBEAM) and Autologous Stem Cell Transplantation (ASCT) for Poor
Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.Gov Identifier:
NCT00530179
3415
Intravenous Busulfan Plus Melphalan Is a Highly
Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell
Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies
3416
Phase III Intergroup Study of Lenalidomide (CC-5013)
Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell
Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient
Accrual and Adverse Events
3417
Prognostic Significance of PET Imaging in Relapsed or
Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and
Autologous Stem Cell Transplantation
3418
Reapplication of High-Dose Chemotherapy and Autologous
Blood Stem Cell Transplantation as Salvage Treatment for Patients with Relapsed
or Refractory Multiple Myeloma – a Single Center Experience
3419
Sequential Approach with Bortezomib as Induction
Before Autologous Transplantation, Followed by Lenalidomide as
Consolidation-Maintenance in Untreated Multiple Myeloma Patients
3420
Stem Cell Transplant (SCT) and Pralatrexate Therapy:
Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who
Received SCT Prior to or Following Pralatrexate Therapy
3421
SUPER- BEAM (SB): Incorporation of Bortezomib,
Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for
Multiple Myeloma (MM)
3422
The Number of CD4+ T-Lymphocytes in the Autograft
Correlates with Outcome After Autologous Stem-Cell Transplantation in Relapsed
Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
3423
Y90 Plus High Dose BEAM with Autologous Stem Cell
Transplantation for Chemorefractory Non Hodgkin Lymphoma Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster
III
3692
Interim and End-of-Treatment
18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma
(DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus
Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in
Spain
3693
A Phase II Multicenter Study of Lenalidomide in
Relapsed or Refractory Classical Hodgkin Lymphoma
3694
Bendamustine Is Highly Effective for Relapsed or
Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell
Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study
3695
Phase I/II Study of Escalating Doses of Idarubicin
Orally Given with Oral Cyclophosphamide, Etoposide, Prednisolone and
Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non
Hodgkin Lymphoma
3696
A Phase I Study of Vorinostat (V) in Combination with
Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with
Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell
Lymphoma
3697
Dose-Dense Weekly Rituximab and Standard CHOP Therapy
in 123 Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma; Ganken
Ariake Lymphoma Study Group Analysis
3698
Clinical Experience of Bendamustine Treatment for
Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Spanish Registry
3699
Identification of Potential Surrogate Endpoints in
Randomized Clinical Trials of Aggressive Non-Hodgkin Lymphoma: Correlation of
Complete Response, Time-to-Event and Overall Survival Data
3700
Phase I/II Study for the Effectivity of Rituximab,
Gemcitabin and Oxaliplatin in Relapsed Indolent Lymphoma – An Interim Report
3701
Characterization of Cyclic Hematologic Changes
Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving
Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor
3702
The Paediatric LMB Protocol Has High Curative
Potential in Adults with Burkitt Lymphoma and High Proliferation DLBCL
3703
Gastric Diffuse Large B-Cell Lymphoma: Analyses of
Prognostic Factors and Value of Pretreatment FDG-PET Scan
3704
Herpesviridae Viral Infections Following Chemotherapy
in Patients with Lymphoma : Incidence, Risk Factors, and Prevention
3705
Escalated BEACOPP Versus ABVD-Like Chemotherapy for
Hodgkin Lymphoma Patients: a Cochrane Review
3706
Rituximab Overcomes Sex as a Strong Adverse Prognostic
Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of
Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German
Low Grade Lymphoma Study Group (GLSG)
3707
Pretransplatation PET as Major Prognostic Discriminant
in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients
with Relapsed/Refractory Hodgkin’s Lymphoma (HL)
3708
Rituximab, Cyclophosphamide, Bortezomib and Prednisone
(R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and
the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory
Indolent and Mantle Cell Lymphomas
3709
Systematic Assessment of Potential Cardiac Effects of
the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin
3710
"No Reduction of Ovarian Failure with the Use of
GnRH-Analogues or Oral Contraceptives in Young Women Treated with Escalated
BEACOPP for Advanced-Stage Hodgkin Lymphoma (HL). Final Results of the PROFE
Trial, German Hodgkin Study Group (GHSG)"
3711
Treating Hodgkin Lymphoma in HIV Positive Patients: a
Comparative Analysis with the HIV Negative Population
3712
Immuno-Chemotherapy with Rituximab, Methotrexate,
Lomustine, and Procarbazine for the Treatment of Primary CNS Lymphoma in
Patients >65 Years
3713
A Phase I Dose Escalation Study of the Btk Inhibitor
PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a
Novel Fluorescent Probe Pharmacodynamic Assay
3714
Outcome of Elderly Patients with DLBCL Failing R-CHOP:
The Role of Rituximab and High Dose Therapy in Second Line Treatment. A
Retrospective Analysis From the RICOVER 60 Trial
3715
Male Sex Is Associated with Lower Rituximab Trough
Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients
with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German
High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL)
3716
Safety and Efficacy of Intrathecal
Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis
in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the
R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study
3717
Pegylated Liposomal Doxorubicin, Bleomycin,
Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary
Cutaneous Lymphomas
3718
The Addition of Bortezomib to Modified R-CHOP as
Initial Therapy for Follicular NHL Results in High CR Rate and Is Well
Tolerated
3719
Enzastaurin in Patients with Non-Hodgkin Lymphomas: A
Multicenter, Open-Label, Screening Study Lymphoma: Therapy with Biologic Agents, excluding
Pre-Clinical Models Poster III
3741
10 Years Follow-up of the GELA LNH98.5 Study, First Randomized
Study Comparing R-CHOP to CHOP Chemotherapy in Patients with Diffuse Large
B-Cell Lymphoma
3742
A Phase I Study of PRO131921, a Novel Anti-CD20
Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL:
Correlation Between Clinical Responses and AUC Pharmacokinetics
3743
A Phase II Trial of R-FM (Rituximab, Fludarabine and
Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan
(90Y-IT) for Untreated Follicular Lymphoma (FL) Patients
3744
Clinical and Biologic Activity of the Heat Shock
Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma
3745
Complete Responses with Denileukin Diftitox in
Cutaneous T-Cell Lymphoma Studies
3746
Consolidation with Radioimmunotherapy May Prolong
Survival in First Remission of Mantle Cell Lymphoma Patients Uneligible for
Stem Cell Transplantation, An Analysis of the International RIT-Network
3747
Cyclophosphamide, Vincristine, Myocet and Prednisone ±
Rituximab (COMP±R) Regimen Is Safe and Effective as First Line or Salvage
Therapy in Elderly Non Hodgkin Lymphoma (NHL): Preliminary Data of Single
Centre Experience
3748
Low-Dose Alemtuzumab Is Uniquely Effective in
Refractory Leukemic Cutaneous T Cell Lymphoma (L-CTCL)
3749
Macrophage Polarization and Acquired Resistance to
Rituximab in CNS Lymphoma
3750
Maintenance Rituximab Is Associated with Improved
Progression Free and Overall Survival in Waldenstrom’s Macroglobulinemia
3751
Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment
as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage,
Bulky Diffuse Large B Cell Lymphoma
3752
Phase II Trial of Weekly Bortezomib in Combination
with Rituximab in Untreated Patients with Waldenstrom’s Macroglobulinemia
3753
Pulmonary Infiltrates in NHL Patients Receiving
Rituximab Combined with Chemotherapy: 18F-Fluorodeoxyglucose Positron Emission
Tomography and CT (PET-CT) Analysis and Clinical Correlates
3754
Rituximab and Chlorambucil as Front-Line Treatment in
Untreated Follicular Lymphoma: a Combination with a Durable Response and Low
Toxicity Profile
3755
Rituximab Does Not Improve Progression Free (PFS) or
Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell
Lymphoma (DLBCL)
3756
Safety and Efficacy in Patients Receiving Maintenance
Rituximab for Follicular Lymphoma: Early Results From Phase IIIb MAXIMA Trial
3757
Subcutaneous Injections of Low Doses of Humanized
Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies
3758
The Combination of Bortezomib and Rituximab Is
Effective and Safe in Relapsed/Refractory Indolent Non Follicular and
Mantle-Cell Non Hodgkin Lymphoma: a Phase II Multicenter Study by Intergruppo
Italiano Linfomi
3759
Tositumomab and Iodine I-131 Tositumomab for
Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year
Follow-up Results Non-Hodgkin's Lymphoma - Biology, excluding Therapy Poster
III
3919
Diagnostic and Therapeutic Implications of Expression
and Phosphorylation of the Translation Regulatory Protein 4E-Binding Protein
(BP)-1 in B-Cell Lymphomas and Reactive Lymphoid Tissues
3920
A Prospective Study Comparing CT, PET and PET/CT for
Pre-Treatment Clinical Staging in Non-Hodgkin's and Hodgkin's Lymphoma
3921
Assessment of Circulating t(14;18)-Positive Cells in
4152 Individuals without Lymphoma Shows Association with Age and Gender, but
Not with Smoking Status: Results From the Population-Based Study of
Health in Pomerania (SHIP)
3922
Bone Loss in Lymphoma Patients Receiving Frontline
Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early
Evidence of Zoledronic Acid Response
3923
Charlson Comorbidity Index Is An Independent
Prognostic Factor Among Elderly Patients with Diffuse Large B-Cell Lymphoma
(DLBCL)
3924
Clinicopathologic Characteristics of HIV-Associated
Peripheral T-Cell Lymphoma
3925
Distinct Interaction Networks of the MUM1/IRF4 in B-
and T-Cell Lymphomas Identified by Tandem Mass Spectrometry
3926
EBV Infection and Altered Control of Apoptotic
Pathways in Posttransplant Lymphoproliferative Disorders (PTLD)
3927
Elevated Expression of GPR34 in Mucosa-Associated
Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth,
Erk Activation, and AP-1 and CRE-Mediated Transcription
3928
Fine Needle Aspiration Biopsy with Flow Cytometry Is a
Reliable Method for Defining Immunophenotype of Prognostic Value in T
Lymphoblastic Lymphoma
3929
GATA-3 Promotes IL-10 Production and Is An Adverse
Prognostic Factor in Peripheral T-Cell Lymphoma Unspecified (PTCL-U)
3930
Gene Expression Profiling Distinguishes Waldenstrom’s
Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS
Prognostic Score, and Previous Treatment with Rituximab
3931
Gene Expression Profiling Reveals Activation of
Multiple Oncogenic Pathways and Over-Expression of Survivin in the Pathogenesis
of Extranodal Nasal-Type NK/T Cell Lymphoma
3932
Genome Wide SNP Analysis Reveals Frequent Cryptic
Clonal Chromosomal Aberrations Including Uniparental Disomy (UPD) in
Waldenstrom’s Macroglobulinemia.
3933
Germline Variation in Apoptosis Pathway Genes and Risk
of Non-Hodgkin Lymphoma
3934
High Incidence of Hepatitis B or C Virus Infection in
Lymphoma
3935
Hyperphosphorylated Paratarg-7 Is a Frequent Antigenic
Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly
Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance
of the IgM Type (IgM-MGUS) and Waldenstrom's Macroglobulinemia (WM), Allowing
for the Identification of Family Members at Risk in Cases of Familial IgM-MGUS
and WM
3936
Identification of Cyclin D1-Dependent Genes by Gene
Expression Profiling in MCL Cell Lines and Primary Cases
3937
Indolent Mantle Cell Lymphoma: A Distinct Subgroup
Characterized by Leukemic Phase Disease without Lymphadenopathy
3938
Inhibition of the RKIP and PTEN-Transcription
Repressor Snail in B-NHL by the Proteasome Inhibitor NPI-0052: Roles of RKIP
and PTEN Induction in the Reversal of Resistance to TRAIL Apoptosis
3939
Interim Analysis of the IELSG-19 Randomised Study of
Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in
Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT
lymphoma)
3940
Junctional Adhesion Molecule C (JAM-C) Constitutes a
New Marker for the Differential Diagnosis of B Cell Lymphomas
3941
Levels of Circulating Endothelial Cells and
Endothelial Progenitors Correlate with Disease Status and Treatment Response in
Human Lymphoma Subtypes of CLL and MCL
3942
Metalloproteinase Inhibitors Inhibit the Release of
Soluble CD27 by Waldenström’s Macroglobulinemia Cells
3943
NIK and the Alternative NF-κB Pathway in Human
Lymphomas
3944
Number of Lymphoma-Associated-Macrophages (LAM) Is An
Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL)
3945
Optimizing Follow up Schedule for Non Hodgkin
Lymphoma' Patients by Multi-Objective Analysis
3946
PIM as a Rational Target for B-Cell Lymphomas
3947
Post Transplant Lymphoproliferative Disorders (PTLD)
After Lung Transplantation: Comparison of Patients with Early Versus Late
Disease
3948
Pre-Treatment Serum Soluble Interleukin-2 Receptor
Value Significantly Predicts Survival in Patients with Newly Diagnosed
Diffuse Large B-Cell Lymphoma
3949
Prognostic Impact of Mid-Treatment PET in Patients
with Diffuse Large B-Cell Lymphoma Who Achieved Metabolic CR at Post-Treatment
PET
3950
Prognostic Significance of Promoter Methylation of
Multiple Genes in Germinal Center Hyperplasia (GCH) and Lymphomas of Germinal
Center Origin
3951
Risk of Second Cancers in Waldenstrom
Macroglobulinemia: a Population-Based Study From Northern Italy
3952
Serum Immunoglobulin Free Light Chain (sFLC)
Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom
Macroglobulinemia (WM)
3953
Several Immune Cell Subsets Are Associated with
Outcome in the Microenvironment of Follicular Lymphoma
3954
Sezary Syndrome Is a Malignancy of Central Memory T
Cells with Skin Homing Properties, While Mycosis Fungoides Is a Malignancy of
Skin Homing Effector Memory T Cells
3955
Simultaneous Detection of BCL2 Translocation and Copy
Number Alteration Including Intrachromosomal Amplification in FL and DLBCL
3956
Single Nucleotide Polymorphisms (SNPs) of FCγRIIA
and FCγRIIIA in Patients with Diffuse Large B-Cell Lymphoma Have No Impact
On Treatment Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma
(DLBCL) Treated with CHOP with and without Rituximab: Results From the
RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymhoma Study Group
(DSHNHL)
3957
Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL)
with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP
3958
The BBAP E3 Ligase Monoubiquitylates Histone H4 at
Lysine 91 and Selectively Modulates the DNA Damage Response in
Chemotherapy-Resistant Lymphomas
3959
The Overexpression of Enhancer of Zeste Homologue 2 Is
Associated with Tumor Proliferation and Aggressive Behavior in Adult T-Cell
Leukemia/Lymphoma
3960
Transformation of Indolent Small B-Cell Lymphoma to
Histiocytic Sarcoma: Report of Two Cases with Molecular/Genetic Evidence of
Clonal Relationship Between Two Morphologically and Immunophenotypically
Distinctive Neoplasms Clinical Results - Autologous Transplantation: Lymphoma and
CLL
877
Autologous Hematopoietic Stem Cell Transplantation
(autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing
Autotransplant Versus Wait and Watch
878
Autologous Stem Cell Transplantation (ASCT) in CLL.
Results of a Phase III Randomized Multicenter Trial
879
Early Autologous Stem Cell Transplantation (autoSCT)
May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic
Leukemia (CLL): Results From the GCLLSG CLL3 Trial
880
Autologous Stem Cell Transplantation and Addition of
Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell
Lymphoma
881
Independent Predictive Value of PET-CT Pre Transplant
in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma
(DLBCL) Included in the CORAL Study
882
A Recent Update of Three Consecutive Prospective
Trials with High-Dose Therapy and Autograft, without or with Rituximab, as
Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable
Group of Patients Surviving in Continuous Complete Remission up to 16 Years
After the End of Treatment: Should We Still Consider FL An Incurable Disease ? Lymphoma: Chemotherapy, excluding Pre-Clinical Models - New
Treatments
919
Pralatrexate Is Active in Cutaneous T-Cell Lymphoma
(CTCL): Results of a Multicenter, Dose-Finding Trial
920
Final Results of a Phase II Trial of Belinostat
(PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous
T-Cell Lymphoma
921
Clofarabine (CLO) Has Single Agent Activity in
Relapsed and Refractory Non-Hodgkin Lymphoma (NHL) Including Rituximab
(R)-Refractory Patients (pts)
922
Evidence of Clinical Activity in a Phase 1 Study of
CAL-101, An Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol
3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies
923
Efficacy of Panobinostat in Phase II Study in
Patients with Relapsed/Refractory Hodgkin Lymphoma (HL) After High-Dose
Chemotherapy with Autologous Stem Cell Transplant
924
Bendamustine, Bortezomib and Rituximab in Patients
(pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL):
a Multicenter Phase II Clinical Trial
931
"Hiper CVAD Followed by Rituximab Purging
Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell
Lymphoma. Results of Manto 2000 study"
932
90y-Ibritumumab Tiuxetan (Zevalin ®)-BEAM/C with
Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell
Lymphoma. – Preliminary Results From the Third Nordic MCL Phase II Study
(MCL3)
933
Bortezomib, Bendamustine, and Rituximab in Patients
with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the
Phase 2 VERTICAL Study
934
A Phase I Study of GA101 (RO5072759) Monotherapy
Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+
Malignant Disease
935
Evaluation of Ofatumumab, a Novel Human CD20
Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular
Lymphoma
936
Patients Treated with Rituximab-Containing
Immunochemotherapy Have a Significant and Prolonged Lack of Humoral Response to
Influenza Vaccine Associated with a Persistent Depletion of B Memory
Cells Non-Hodgkin's Lymphoma - Biology, excluding Therapy:
Non-Hodgkin's Lymphoma: Biology
967
Clinical Impact of TP53 Gene Mutations in Diffuse
Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium
Program Study
968
Differential JAK-STAT Pathway Activation in Primary
Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential
Cytokine Activation Patterns and Predicted Responses to Kinase
Inhibitors
969
Peripheral T-Cell Lymphoma. Molecular Heterogeneity
Revealed by Integrative Genomic Analysis
970
Increased Immune Suppressive CD14+ hla-DRneg
Circulating Monocytes Are Found in Aggressive Non-Hodgkin’s Lymphoma and
Correlated with Increased Arginase I Level
971
Aberrations of Genes Regulating NF Kappa B Pathway in
B-Cell Malignant Lymphoma
972
The Role of ETV6/TEL in Hematopoiesis and Lymphoid
Neoplasia